Familial chylomicronemia syndrome is a rare inherited disease that prevents the body from breaking down lipids. Redemplo ...
Totality of evidence” approach to evaluate SCENESSE®EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its “totality of evidence” ...
Palbociclib slows cancer cell proliferation in patients with HR+/HER2- locally advanced or metastatic breast cancer.
The European Medicines Agency (EMA) has finalized a document with recommendations on using the European Medicines Regulatory Network (EMRN) Data Quality Framework (DQF) when submitting premarket ...
The trend for the timing of initial marketing authorization applications (MAAs) to be less predictable is slowly reversing ...
Off-patent medicines provide people with access to high-quality essential treatment options that can be significantly less expensive than branded on-patent medicines. Off-patent therapies — generics ...
The reform grants eight years of regulatory data and market protection, with extensions for drugs addressing unmet needs. EMA's procedures will be streamlined, reducing assessment times and ...
10d
EMA Webinar to Explore How AI-Driven Observability Connects IT Performance to Real Business Impact
Enterprise Management Associates (EMA™), a leading IT research and consulting firm, today announced it will host a webinar, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results